Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sonata launches to engineer cells’ microenvironments

by Jessica Marshall
May 20, 2022 | A version of this story appeared in Volume 100, Issue 18

 

Flagship Pioneering has launched Sonata Therapeutics, which aims to treat disease by engineering the microenvironment of cells. The company will use small-molecule and genetic approaches along with analytical techniques and machine learning to develop treatments based on cellular microenvironments. Its first targets are cancer, fibrosis, and autoimmune disorders. Sonata is the latest of many companies launched by Flagship, a biotech venture capital firm.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.